BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6782668)

  • 1. [Estulic in the long-term treatment of hypertension].
    Rhomberg F
    Schweiz Med Wochenschr; 1980 Dec; 110(50):1922-4. PubMed ID: 6782668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term antihypertensive therapy with guanfacine.
    Szám I; Holló J
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):388-92. PubMed ID: 6749702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):279-87. PubMed ID: 7030975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and tolerance of the antihypertensive agent guanfacine.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):170-4. PubMed ID: 6370876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension.
    Board AW; Perry VP; Shepperson BE; Nyman CE; Carchman SH
    Clin Ther; 1988; 10(6):761-75. PubMed ID: 3064907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.
    Mayer O; Polívková H
    Cor Vasa; 1987; 29(4 Suppl 1):37-41. PubMed ID: 3315449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanfacine: a new centrally-acting antihypertensive agent.
    Beevers DG; Bloxham CA; Walker JM
    Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new antihypertensive agent used in a clinical setting].
    Wetzels E; Raschig A; Kaiser HJ
    Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guanfacine versus alpha-methyldopa in benign essential hypertension. An ambulatory group study].
    Rhomberg F; Widler J
    Schweiz Med Wochenschr; 1981 Dec; 111(50):1967-8. PubMed ID: 7036334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pharmacology of the antihypertensive action of guanfacine].
    Safar M; Weiss Y; Georges D
    Arch Mal Coeur Vaiss; 1980 Oct; 73(10):1171-7. PubMed ID: 6778409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antihypertensive therapy with guanfacine. A multicenter study with Estulic-Wander 1mg. Determinants of effectiveness and tolerance].
    Schäfer N; Knaup G
    Med Welt; 1983 Feb; 34(5):158-61. PubMed ID: 6341756
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of small doses of guanfacine (Estulic Sandoz) on the lipid levels and catecholamine excretion in patients with essential hypertension.
    Balazovjech I; Skultétyová D; Mikulecký M; Kratochvíl'ová H
    Cor Vasa; 1987; 29(4 Suppl 1):46-52. PubMed ID: 3315451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of the antihypertensive action of long-term estulic (Egis-Sandoz) treatment.
    Zeher M; Antal L; Azad AQ; Szegedi G
    Ther Hung; 1988; 36(3):103-8. PubMed ID: 3074520
    [No Abstract]   [Full Text] [Related]  

  • 15. [Circadian changes in arterial blood pressure and hemodynamics and the morphofunctional state of the myocardium in patients with hypertension during long-term treatment with estulic].
    Komarov FI; Ol'binskaia LI; Iamshchikov SN
    Klin Med (Mosk); 1990 Feb; 68(2):58-61. PubMed ID: 2186218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new centrally action antihypertensive agent guanfacine (BS 100-141).
    Dubach UC; Huwyler R; Radielovic P; Singeisen M
    Arzneimittelforschung; 1977; 27(3):674-6. PubMed ID: 326262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of arterial hypertension with a single daily dose of guanfacine].
    Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC
    Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438
    [No Abstract]   [Full Text] [Related]  

  • 18. [Controlled doubleblind study on dose-effect relationship of guanfacine a long-acting hypotensive guanidine derivative (author's transl)].
    Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G
    Arzneimittelforschung; 1980; 30(6):1005-7. PubMed ID: 6998487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of estulic in patients with arterial hypertension].
    Kukes VG; Spasskiĭ AV; Alkhazov AI; Rudakov AG; Zisel'man SB
    Sov Med; 1985; (12):57-61. PubMed ID: 3913006
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved exercise performance of hypertensive patients treated with guanfacine (Estulic Sandoz).
    Bazika V
    Cor Vasa; 1987; 29(4 Suppl 1):42-5. PubMed ID: 3315450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.